ANNUAL REPORT 2021
LUNDBECK
ANNUAL REPORT 2021
= CONTENTS
Pipeline
PROJECT
BIOLOGY
AREA
Eptinezumab (anti-CGRP mAb)1
Eptinezumab (anti-CGRP mAb)
Eptinezumab (anti-CGRP mAb)
Lu AG09222 (anti-PACAP mAb)³
Hormonal /
neuropeptide
signaling
Migraine prevention
Migraine prevention (Asia)²
Episodic cluster headache
Migraine prevention
Brexpiprazole4
Brexpiprazole4
Aripiprazole 2-month injectable formulation
Lu AF28996 (D1/D27 agonist)
Lu AG06466 (MAGL inhibitor)³
Circuitry /
neuronal biology
Agitation in Alzheimer's disease
PTSD5
Schizophrenia & bipolar I disorder
Parkinson's disease
Focal epilepsy/PTSD5/MS spasticity⁹
Lu AF82422 (anti-a-synuclein mAb)
Protein aggregation,
folding and clearance
Synucleinopathies (MSA10)
Lu AF87908 (anti-Tau mAb)
Tauopathies
Three phase III clinical trials, supporting registration in Asia, including China and Japan: SUNLIGHT, SUNRISE, and SUNSET trials
PACAP: Pituitary adenylate cyclase activating peptide
1) CGRP: Calcitonin gene-related peptide
2)
3)
4)
5)
Acts as a partial agonist at 5-HT1A and dopamine D2 receptors at similar potency, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors
Post-traumatic stress disorder
6) Pivotal phase lb study finalized; Lundbeck and Otsuka Pharmaceutical are planning to submit the aripiprazole 2-month injectable formulation to the European
Medicines Agency (EMA) for marketing authorization application (MAA) review and to submit the NDA for review by the U.S. FDA
7) Dopamine receptor D1 and D2
8) MAGL: Monoacylglycerol lipase i ("MAGlipase")
9) Spasticity in participants with Multiple Sclerosis
10) Multiple system atrophy
28/111
PHASE I
PHASE II
PHASE III
FILING / LAUNCHView entire presentation